We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

By LabMedica International staff writers
Posted on 17 May 2023
Print article
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints in laboratory workflows and staffing can lead to delays in providing test results to physicians and patients. A new pair of hematology analyzers now addresses these issues by offering user-friendly interfaces and the ability to connect multiple analyzers, effectively eliminating workflow bottlenecks and delivering the fast processing times needed in high-volume labs. These analyzers also offer integrated rules-based testing, which allows lab technicians of varying experience levels to interpret complex patient results and respond promptly.

Siemens Healthineers (Erlangen, Germany) has introduced two novel solutions for high-volume hematology testing, the Atellica HEMA 570 Analyzer and the Atellica HEMA 580 Analyzer. The complete blood count (CBC), a vital component of patient care, is one of the most frequently conducted diagnostic tests in the lab and often provides the first sign of a patient's illness. Physicians rely heavily on labs to deliver crucial hematology data reliably. Traditionally, hematology testing is a complex, time-sensitive process that necessitates skilled laboratory personnel to evaluate results before they can be relayed to physicians. The widespread use of CBC testing and escalating staff shortages can impact a lab's capacity to quickly review and release patients' test results. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers offer integrated automation and intelligence designed to overcome these challenges, thereby enhancing workflow efficiency and speeding up patient results delivery.

In hospital or critical care settings, the expected turnaround time for routine CBCs is typically less than an hour, while for STATs, it is ideally less than 10 minutes. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers can generate a throughput of up to 120 tests per hour. Their intuitive designs significantly decrease time-intensive daily maintenance while enabling quick reagent changes. Patients in critical condition, such as those with cancer, renal conditions, or neonates, require hematology testing to monitor their progress and guide adjustments to their care. Small changes in patient results can have significant implications if they are not flagged or if they are misinterpreted. The Atellica HEMA 570 and Atellica HEMA 580 Analyzers incorporate advanced data management capabilities to address the expertise gap in labs, thus enabling staff of all skill levels to interpret results accurately.

The analyzers' rules-based auto-validation feature can release normal results—those that do not violate predefined criteria—directly into a laboratory information system, thereby saving time and enabling physicians to receive information more quickly. Any abnormalities are flagged and categorized by severity to clearly signify which patient samples need more detailed examination by a technician. When results necessitate further steps such as dilutions or slide reviews, standardized instructions can be displayed to ensure staff follows lab protocols. The Atellica HEMA 570 Analyzer measures 43 cell parameters, while the Atellica HEMA 580 Analyzer offers an additional 12 parameters, including indicators of immature red blood cells relevant to certain patient populations and an optical-based platelet count that reduces analytical interferences common in other detection technologies. Up to six Atellica HEMA 570 and Atellica HEMA 580 Analyzers can be integrated together to maximize throughput with intelligent, automated workload balancing and reflexive testing that minimizes operator involvement.

"We hear from labs that they need agility, reliability, and speed," said Sharon Bracken, Head of Diagnostics, Siemens Healthineers. "The Atellica HEMA analyzers combine workflow improvements with demonstrated technology to bring hematology testing into the future. We're delivering the breakthroughs labs need to produce quality patient results faster."

Related Links:
Siemens Healthineers 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.